Suppliers and packagers for ZIDOVUDINE

ZIDOVUDINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma Ltd	ZIDOVUDINE	zidovudine	CAPSULE;ORAL	078128	ANDA	Aurobindo Pharma Limited	65862-107-01	100 CAPSULE in 1 BOTTLE (65862-107-01)	2006-03-27
Aurobindo Pharma Ltd	ZIDOVUDINE	zidovudine	CAPSULE;ORAL	078128	ANDA	Aurobindo Pharma Limited	65862-107-10	10 BLISTER PACK in 1 CARTON (65862-107-10) / 10 CAPSULE in 1 BLISTER PACK	2006-03-27
Aurobindo	ZIDOVUDINE	zidovudine	SOLUTION;ORAL	077268	ANDA	Aurobindo Pharma Limited	65862-048-24	240 mL in 1 BOTTLE (65862-048-24)	2005-09-19

Zidovudine Suppliers Analysis

Last updated: February 19, 2026

This report details key suppliers for the pharmaceutical drug zidovudine, focusing on manufacturing capabilities, regulatory compliance, and market presence. Zidovudine, an antiretroviral medication, is critical in HIV/AIDS treatment. Identifying reliable suppliers is essential for ensuring consistent drug supply chains and patient access.

Who are the Primary Manufacturers of Zidovudine?

Major pharmaceutical companies and contract manufacturing organizations (CMOs) are involved in the production of zidovudine active pharmaceutical ingredient (API) and finished drug products. These entities operate under stringent regulatory oversight to maintain quality and safety standards.

• API Manufacturers:

  • Aspen Pharmacare Holdings Limited: A global pharmaceutical company with significant manufacturing capabilities, including antiretrovirals. Aspen produces zidovudine API at its facilities.
  • Viatris Inc. (formerly Mylan N.V.): A global healthcare company formed by the merger of Mylan and Pfizer's Upjohn business. Viatris is a substantial producer of generic pharmaceuticals, including zidovudine API and finished dosage forms.
  • Cipla Limited: An Indian multinational pharmaceutical company that manufactures and markets a wide range of generic drugs. Cipla has been a long-standing supplier of zidovudine.
  • Strides Pharma Science Limited: An integrated pharmaceutical company with a global presence, engaged in the development, manufacturing, and commercialization of a wide range of products, including antiretrovirals like zidovudine.
  • Aurobindo Pharma Limited: A vertically integrated pharmaceutical company that manufactures and markets generic and branded pharmaceuticals, including APIs for antiretroviral drugs.

• Finished Dosage Form Manufacturers (including those sourcing API from external suppliers):

  • GlaxoSmithKline plc (GSK): The originator of zidovudine (Retrovir). While the patent has expired, GSK continues to be involved in its distribution and may still engage in its manufacturing or have contract manufacturing agreements.
  • BMS Pharmaceuticals: Bristol Myers Squibb was involved with zidovudine. Similar to GSK, their direct manufacturing role may be through legacy products or contract arrangements.
  • Various Generic Pharmaceutical Companies: Numerous companies worldwide, particularly in India and China, manufacture generic zidovudine tablets and oral solutions. These include companies like Zydus Lifesciences (formerly Cadila Healthcare), Dr. Reddy's Laboratories, and numerous smaller regional players.

What are the Regulatory Standards for Zidovudine Production?

Zidovudine production is subject to rigorous regulatory standards to ensure product quality, safety, and efficacy. These standards are enforced by national and international health authorities.

• Good Manufacturing Practices (GMP):
  • FDA GMP: The U.S. Food and Drug Administration (FDA) enforces Current Good Manufacturing Practice (CGMP) regulations (21 CFR Parts 210 and 211) for all pharmaceutical manufacturing facilities in the United States and those exporting to the U.S. [1]. These regulations cover quality systems, personnel, facilities and equipment, process controls, packaging, and labeling.
  • EMA GMP: The European Medicines Agency (EMA) also mandates GMP compliance for drugs sold within the European Union. Manufacturers must adhere to EU GMP guidelines.
  • WHO GMP: The World Health Organization (WHO) provides GMP guidelines that are adopted by many countries, particularly in developing nations.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the FDA. A DMF contains proprietary information about the facilities, processes, and materials used in manufacturing, processing, packaging, and storing the API. This allows regulatory bodies to review the API's quality without disclosing proprietary information to the finished drug product manufacturer [2].
• Inspections and Audits: Manufacturing facilities are subject to periodic inspections by regulatory authorities to verify compliance with GMP. Customers (finished drug product manufacturers) also conduct their own audits of API suppliers.
• Quality Control Testing: Each batch of zidovudine API and finished product must undergo comprehensive quality control testing, including assays for potency, purity, identification, and impurity profiling, to meet pharmacopeial standards (e.g., United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.)).

What is the Supply Chain Structure for Zidovudine?

The zidovudine supply chain involves API manufacturers, formulation sites, packaging and labeling operations, and distributors, ultimately reaching patients through pharmacies and healthcare providers.

• API Sourcing: Finished drug product manufacturers either produce zidovudine API in-house or source it from specialized API manufacturers. Key sourcing regions for generic APIs include India and China, known for their cost-effective manufacturing.
• Formulation and Manufacturing: API is then formulated into finished dosage forms, such as tablets, capsules, or oral solutions. This process involves blending the API with excipients, granulation, compression (for tablets), or encapsulation.
• Packaging and Labeling: Finished products are packaged into bottles, blister packs, or other suitable containers and labeled according to regulatory requirements. This includes dosage information, warnings, batch numbers, and expiry dates.
• Distribution: Pharmaceutical distributors then transport the finished product to wholesalers, hospitals, and retail pharmacies globally.
• Global Health Initiatives: Organizations like the Global Fund to Fight AIDS, Tuberculosis and Malaria, and PEPFAR (U.S. President's Emergency Plan for AIDS Relief) play a significant role in procuring and distributing zidovudine-containing antiretroviral therapies, particularly in low- and middle-income countries.

What are the Key Considerations for Sourcing Zidovudine API?

Sourcing zidovudine API requires careful evaluation of several factors to ensure reliability, quality, and cost-effectiveness.

• Manufacturing Capacity and Reliability:
  • Production Volume: Assess the supplier's ability to meet current and future demand.
  • Lead Times: Understand production and delivery timelines.
  • Contingency Planning: Evaluate the supplier's business continuity plans for supply disruptions.
• Quality Assurance and Regulatory Compliance:
  • GMP Certification: Verify current GMP certifications from relevant authorities (FDA, EMA, etc.).
  • Audit History: Review past audit findings and corrective actions.
  • DMF Status: Ensure DMFs are up-to-date and accepted by target markets.
  • Quality Control Processes: Inquire about raw material testing, in-process controls, and finished API release testing.
• Cost and Pricing Stability:
  • API Price: Obtain competitive quotes considering volume and contract terms.
  • Price Volatility: Understand factors that may influence price fluctuations.
  • Total Cost of Ownership: Include shipping, import duties, and quality control costs.
• Technical Support and Documentation:
  • Certificate of Analysis (CoA): Ensure CoAs are detailed and meet specifications.
  • Impurity Profiles: Obtain comprehensive impurity data and control strategies.
  • Technical Expertise: Access to technical support for formulation or analytical challenges.
• Geopolitical and Supply Chain Risks:
  • Geographic Diversification: Consider sourcing from multiple regions to mitigate risk.
  • Political Stability: Evaluate the political environment in the supplier's country of operation.
  • Logistics and Transportation: Assess the reliability of shipping routes and carriers.

Which Markets are Major Consumers of Zidovudine?

Zidovudine consumption is concentrated in regions with high HIV/AIDS prevalence, supported by national treatment programs and global health initiatives.

• Sub-Saharan Africa: This region accounts for the largest proportion of global HIV cases and, consequently, antiretroviral therapy demand. Countries like South Africa, Nigeria, and Kenya are significant consumers.
• Asia: Countries with substantial HIV populations, including India, Thailand, and Vietnam, are key markets.
• Latin America and the Caribbean: Countries such as Brazil, Mexico, and Haiti have ongoing demand for HIV treatment.
• North America and Europe: While prevalence may be lower than in Sub-Saharan Africa, these regions maintain consistent demand due to established healthcare systems and long-term HIV management.
• Global Health Program Procurement: Large-scale procurements by organizations like the Global Fund and PEPFAR significantly influence market demand and supply dynamics, particularly in resource-limited settings. These programs often procure combination therapies that include zidovudine.

What are the Key Trends and Challenges in the Zidovudine Market?

The zidovudine market is influenced by evolving treatment guidelines, generic competition, and supply chain complexities.

• Shift in Treatment Guidelines:
  • First-line Therapy: International guidelines have increasingly shifted towards integrase inhibitors and tenofovir-based regimens as preferred first-line HIV treatments. Zidovudine is often relegated to second-line or salvage therapy, or used in specific patient populations.
  • Fixed-Dose Combinations (FDCs): Zidovudine remains an important component of several widely used FDCs, such as AZT/3TC (zidovudine/lamivudine) and AZT/3TC/NVP (zidovudine/lamivudine/nevirapine), which simplify treatment adherence.
• Generic Competition: The market is largely driven by generic manufacturers, leading to price pressures and a focus on cost-efficient production.
• Supply Chain Resilience: Ensuring a stable supply of essential medicines like zidovudine is a continuous challenge, exacerbated by global events, geopolitical instability, and single-sourcing risks.
• Quality Control and Counterfeiting: The generic market necessitates vigilant quality control to prevent substandard or counterfeit drugs from entering the supply chain.
• Emerging Markets Focus: The majority of demand, particularly for FDCs containing zidovudine, originates from emerging economies where access to advanced therapies may be limited or prohibitively expensive.

Key Takeaways

• Aspen Pharmacare, Viatris, Cipla, Strides Pharma Science, and Aurobindo Pharma are significant manufacturers of zidovudine API.
• Production must adhere to stringent GMP standards enforced by regulatory bodies like the FDA and EMA.
• The supply chain involves API manufacturers, formulators, distributors, and is heavily influenced by global health initiatives.
• Key sourcing considerations include manufacturing capacity, regulatory compliance, cost, and supply chain risks.
• Sub-Saharan Africa represents the largest market for zidovudine due to high HIV prevalence.
• Market trends include shifts in treatment guidelines away from zidovudine as first-line therapy and intense generic competition.

Frequently Asked Questions

1. What is the primary use of zidovudine? Zidovudine is an antiretroviral medication used in the treatment of HIV/AIDS, often as part of a combination therapy regimen. It is also used to prevent mother-to-child transmission of HIV.
2. Are there any specific quality certifications required for zidovudine API suppliers? Suppliers are expected to have current Good Manufacturing Practice (GMP) certifications from relevant regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Drug Master Files (DMFs) are also critical for API sourcing.
3. How does global health initiatives impact the zidovudine market? Global health organizations like the Global Fund and PEPFAR are major procurers of zidovudine-containing antiretroviral therapies, significantly influencing demand and supply dynamics, especially in low- and middle-income countries.
4. What are the main challenges in maintaining a stable zidovudine supply chain? Challenges include ensuring manufacturing capacity, managing lead times, mitigating geopolitical and logistical risks, and combating the threat of counterfeit or substandard products.
5. Has the role of zidovudine in HIV treatment changed over time? Yes, international treatment guidelines have evolved, often recommending other drug classes as preferred first-line HIV therapies. Zidovudine's use has shifted towards second-line therapy, salvage regimens, or its inclusion in fixed-dose combinations.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-inspections/current-good-manufacturing-practice-cgmp-regulations

[2] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/forms-and-fees/drug-master-files